AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

Med Tech segment delivers fifth consecutive quarter of double-digit growth Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals Raised full year FY 2026 guidance